Pulmonary Arterial Hypertension (PAH): Causes, Risk Factors, and Classification

Pulmonary arterial hypertension (PAH) is a progressive disorder defined by a mean pulmonary arterial pressure ≥20 mmHg at rest (per 2022 ESC/ERS guidelines), caused by obstructive remodeling of the small pulmonary arteries. This increases right ventricular afterload, leading to right heart failure and premature death if untreated.

Etiology & Risk Factors

While the exact trigger is often unknown, several factors are implicated:

  • Genetics: Mutations in BMPR2 (bone morphogenetic protein receptor type 2) account for ~75% of heritable PAH and ~20% of idiopathic cases. Other genes (ACVRL1, ENG, SMAD9, KCNK3, CAV1) are also linked.
  • Associated Conditions (Associated PAH – APAH):
    • Connective tissue diseases (systemic sclerosis, lupus, mixed connective tissue disease)
    • Congenital heart disease (especially unrepaired systemic-to-pulmonary shunts)
    • Portal hypertension / cirrhosis (portopulmonary hypertension)
    • HIV infection
    • Chronic hemolytic anemias (sickle cell, thalassemia)
  • Drug & Toxin Exposure:
    • Anorexigens (fenfluramine, dexfenfluramine, benfluorex)
    • Amphetamines, methamphetamine, cocaine
    • Certain chemotherapeutics (dasatinib)
  • Chronic Thromboembolic Disease: Chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 3) can mimic PAH but has distinct pathophysiology and treatment (pulmonary endarterectomy).
  • Age & Sex: Idiopathic PAH peaks in the 4th–5th decades; females are affected 2–4× more often than males.

Classification

  • Idiopathic PAH (IPAH): No identifiable cause after thorough workup (~40–50% of cases).
  • Heritable PAH (HPAH): Family history or pathogenic mutation identified.
  • Associated PAH (APAH): Linked to conditions above.
  • Drug/Toxin-Induced PAH: Temporal relationship with exposure.

Diagnostic Clues

Echocardiography estimates pulmonary pressures; right heart catheterization confirms diagnosis. Early referral to a PH specialist center improves outcomes, as targeted therapies (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin pathway agonists, sGC stimulators) can delay progression and improve quality of life.

Hypertension - Related Articles